β | t | p-value | |
---|---|---|---|
LV GLS endocardium (R2 = 0.327) | |||
Age | −0.170 | −1.48 | 0.142 |
Female gender | −0.112 | −1.22 | 0.225 |
Body mass index | 0.046 | 0.49 | 0.626 |
Diabetes mellitus | 0.062 | 0.66 | 0.511 |
Peripheral SBP | 0.024 | 0.26 | 0.795 |
LV ejection fraction | −0.419 | −4.44 | <0.001 |
LV mass index | −0.001 | −0.01 | 0.995 |
Use of RAAS blocker | 0.158 | 1.76 | 0.082 |
PWV | 0.223 | 2.19 | 0.031 |
LV GCS endocardium (R2 = 0.164) | |||
Age | 0.190 | 1.21 | 0.231 |
Female gender | −0.130 | −1.06 | 0.294 |
Body mass index | 0.076 | 0.63 | 0.534 |
Diabetes mellitus | 0.108 | 0.87 | 0.385 |
Peripheral SBP | 0.004 | 0.04 | 0.970 |
LV ejection fraction | −0.293 | −2.35 | 0.022 |
LV mass index | −0.015 | −0.13 | 0.896 |
Use of RAAS blocker | −0.091 | −0.76 | 0.448 |
Log Aldosterone | 0.201 | 1.61 | 0.112 |
LA GLS (R2 = 0.361) | |||
Age | −0.118 | −1.05 | 0.297 |
Female gender | −0.096 | −1.06 | 0.292 |
Body mass index | −0.179 | −1.94 | 0.055 |
Diabetes mellitus | −0.158 | −1.70 | 0.092 |
Peripheral SBP | −0.044 | −0.50 | 0.622 |
LV ejection fraction | 0.218 | 2.35 | 0.021 |
LV mass index | −0.065 | −0.74 | 0.461 |
Use of RAAS blocker | −0.318 | −3.59 | 0.001 |
PWV | −0.311 | −3.12 | 0.002 |